Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.78 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23201752 | 0.90 | MAPK14 (0.77) | MAPK14MAPK13ABL1ERBB2MAPK11 | |
| SCHEMBL23201771 | 0.89 | MAPK14 (0.80) | MAPK14MAPK13 | |
| SCHEMBL29844362 | 0.88 | MAPK14 (1.00) | MAPK14MAPK13 | |
| SCHEMBL23201717 | 0.88 | MAPK14 (1.00) | MAPK14MAPK13 | |
| SCHEMBL23201684 | 0.86 | MAPK14 (0.80) | MAPK14MAPK13 | |
| SCHEMBL29844109 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13 | |
| SCHEMBL23637689 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13 | |
| SCHEMBL25916915 | 0.83 | MAPK14 (0.80) | MAPK14MAPK13 | |
| SCHEMBL25641493 | 0.83 | MAPK14 (0.88) | MAPK14MAPK13 | |
| SCHEMBL23201658 | 0.81 | MAPK14 (0.77) | MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802525-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2021-04-14 | — | — | EP | claimed |
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3802525-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885ABL1 168/4885 |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885ABL1 168/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885ABL1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.